Themis Medicare Ltd Gains 4.62%: Key Intraday Surges and Financial Struggles Shape the Week

2 February 2026: Stock Hits 52-Week Low Amid Financial Struggles

Themis Medicare Ltd’s share price fell sharply to a 52-week low of Rs.76 on 2 February 2026, closing the day at Rs.77.55, down 3.66%. This decline extended a two-day losing streak, with the stock dropping 4.68% over that period. The fall was driven by ongoing financial difficulties, including four consecutive quarters of negative earnings and deteriorating profitability metrics. The company’s latest quarterly profit before tax excluding other income was a loss of Rs.6.69 crore, a 152.0% decline compared to the prior four-quarter average, while the profit after tax was negative Rs.3.62 crore, down 59.6%.

Despite the broader market’s resilience, with the Sensex falling only 1.03% that day, Themis Medicare underperformed its sector and the benchmark index. The stock traded below all key moving averages, signalling sustained downward momentum. The company’s return on capital employed for the half-year was negative at -3.47%, and its operating profit has declined at an annualised rate of 189.22% over five years, highlighting persistent operational challenges.

3 February 2026: Strong Gap Up and Intraday Rally Signal Short-Term Recovery

On 3 February, Themis Medicare Ltd reversed course with a robust gap up of 9.59% at market open, surging from Rs.77.55 to an intraday high of Rs.84.99. The stock closed at Rs.81.64, up 5.27% on the day, outperforming the Pharmaceuticals & Biotechnology sector’s 2.73% gain and the Sensex’s 2.63% advance. This strong start reflected renewed buying interest and positive market momentum, despite the stock remaining below its longer-term moving averages.

Technical indicators presented a mixed picture: while the stock closed above its 5-day moving average, it remained below the 20-day, 50-day, 100-day, and 200-day averages, indicating that the longer-term downtrend has yet to be broken. The stock’s high beta of 1.85 contributed to amplified price swings, consistent with the sharp gap up and intraday strength observed. Despite this short-term rally, bearish signals from MACD, Bollinger Bands, and Dow Theory on weekly and monthly charts suggested caution.

4 February 2026: Continued Uptrend Amid Sector Gains

The upward momentum extended into 4 February, with Themis Medicare Ltd closing at Rs.85.36, a 4.56% gain on the day. This marked the week’s highest closing price, reflecting sustained buying interest following the previous day’s gap up. The stock outperformed the Sensex, which rose 0.37%, and maintained its position above the 5-day moving average, though it remained below longer-term averages.

The broader Pharmaceuticals & Biotechnology sector continued to show strength, supporting the stock’s rally. However, the company’s longer-term fundamentals remain under pressure, with a Mojo Score of 17.0 and a Strong Sell rating from MarketsMOJO, reflecting ongoing financial and operational challenges.

5-6 February 2026: Minor Pullback and Consolidation

On 5 February, Themis Medicare Ltd experienced a slight pullback, closing at Rs.84.02, down 1.57% from the previous day. The stock’s volume also declined, indicating some profit-taking or consolidation after the recent gains. The Sensex fell 0.53% on the same day, reflecting a broader market pause.

The following day, 6 February, the stock marginally recovered, closing at Rs.84.22, up 0.24%. The Sensex gained 0.10%, signalling a cautious market environment. The stock’s price action during these two days suggests a period of consolidation after a strong rally, with investors assessing the sustainability of the recent gains amid the company’s challenging fundamentals.

Daily Price Comparison: Themis Medicare Ltd vs Sensex

Key Takeaways

Themis Medicare Ltd’s week was characterised by a sharp rebound from a 52-week low, with a 4.62% weekly gain outperforming the Sensex’s 1.51% rise. The strong gap up and intraday surge on 3 February highlighted renewed buying interest and short-term momentum. However, the stock remains below key longer-term moving averages, and technical indicators on weekly and monthly charts continue to signal bearish trends.

Financially, the company faces significant challenges, including consecutive quarterly losses, negative return on capital employed, and a downgrade to a Strong Sell rating by MarketsMOJO. The stock’s high beta contributes to volatility, amplifying price swings in response to market and sector developments.

Investors should note the mixed signals: short-term strength amid longer-term weakness, and the need for sustained improvement in fundamentals to support a durable recovery. The stock’s performance relative to the Pharmaceuticals & Biotechnology sector and the Sensex underscores its ongoing struggle to regain investor confidence.

Conclusion

Themis Medicare Ltd’s performance over the week ending 6 February 2026 reflects a tentative recovery from recent lows, driven by strong intraday gains and a positive gap up. Despite this, the company’s financial difficulties and bearish technical outlook temper optimism. The stock’s outperformance of the Sensex is notable but should be viewed in the context of persistent operational challenges and a cautious rating outlook. Continued monitoring of price action, volume trends, and fundamental developments will be essential to assess whether this week’s gains mark a turning point or a temporary reprieve within a broader downtrend.

Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →